在接受免疫检查点抑制剂治疗的肿瘤中使用外周免疫炎症血液标志物：一项INVIDIa - 2研究的亚分析。
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.
作者信息
Anpalakhan Shobana, Signori Alessio, Cortellini Alessio, Verzoni Elena, Giusti Raffaele, Aprile Giuseppe, Ermacora Paola, Catino Annamaria, Pipitone Stefania, Di Napoli Marilena, Scotti Vieri, Mazzoni Francesca, Guglielmini Pamela F, Veccia Antonello, Maruzzo Marco, Schinzari Giovanni, Casadei Chiara, Grossi Francesco, Rizzo Mimma, Montesarchio Vincenzo, Verderame Francesco, Mencoboni Manlio, Zustovich Fable, Fratino Lucia, Accettura Caterina, Cinieri Saverio, Tondini Carlo Alberto, Camerini Andrea, Banzi Maria Chiara, Sorarù Mariella, Zucali Paolo Andrea, Vignani Francesca, Ricciardi Serena, Russo Antonio, Cosenza Agnese, Di Maio Massimo, De Giorgi Ugo, Pignata Sandro, Giannarelli Diana, Pinto Carmine, Buti Sebastiano, Fornarini Giuseppe, Rebuzzi Sara Elena, Rescigno Pasquale, Addeo Alfredo, Banna Giuseppe L, Bersanelli Melissa
机构信息
Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
University of Genoa, Genoa, Italy.
出版信息
iScience. 2023 Sep 22;26(11):107970. doi: 10.1016/j.isci.2023.107970. eCollection 2023 Nov 17.
The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been reported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosticators in NSCLC, RCC, and melanoma treated with ICIs.
中性粒细胞与淋巴细胞比值（NLR）和全身免疫炎症指数（SII）已被报道为非小细胞肺癌（NSCLC）、肾细胞癌（RCC）和黑色素瘤的预后指标。这项对接受免疫检查点抑制剂（ICI）治疗的癌症患者进行流感疫苗接种的INVIDIa-2研究分析，通过文献报道（LR）、受试者工作特征曲线（ROC）得出的（ROC）临界值或作为连续变量（CV）来评估NLR和SII对总生存期（OS）的影响。在多变量分析中，ROC临界值<3.4（p<0.001）和<831（p<0.001）的NLR和SII是OS的独立因素。SII采用LR、ROC或CV时，在NSCLC（p=0.002，p=0.003，p=0.003）、RCC（p=0.034，p=0.014，p=0.014）和黑色素瘤（p=0.038，p=0.022，p=0.019）中均显著预测OS。采用LR和ROC临界值的NLR在一线（两者p<0.001）和二线及以后（两者p=0.006）预测OS；同样，SII（p<0.001；p=0.002和p<0.001）。NLR和SII是接受ICI治疗的NSCLC、RCC和黑色素瘤的预后指标。
Zotero 插件